You have 9 free searches left this month | to do more
Showing 1 - 25 of
>10,000 items
Trials Per Page
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
C
Study of Mivavotinib (CB-659) in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Not yet recruiting
  • Non-GCB/ABC Diffuse Large B-Cell Lymphoma
  • With and Without MyD88 and/or CD79B Mutations
  • (no location specified)
2022-04-01
Apr 1, 2022
A
A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL)
Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • (no location specified)
2022-02-22
Feb 22, 2022
S
A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)
Recruiting
  • Diffuse Large B-cell Lymphoma
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai JiaoTong University School of Medicine
2021-12-30
Dec 30, 2021
C
A Study of TQ-B3525 in Subjects With Relapse/Refractory Diffuse Large B-cell Lymphoma （DLBCL）
Recruiting
  • Diffuse Large B-cell Lymphoma
  • TQ-B3525 tablets
  • Beijing, Beijing, China
  • +1 more
2021-08-17
Aug 17, 2021
S
Relapsed or Refractory Primary Diffuse Large B-cell Lymphoma (DLBCL) of the Central Nervous System (CNS)
Not yet recruiting
  • DLBCL
  • Seoul, Korea, Republic of
    Seoul National University Hospital
2022-02-15
Feb 15, 2022
N
Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)
Withdrawn
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • Tisagenlecleucel
  • (no location specified)
2022-02-25
Feb 25, 2022
U
A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)
Active, not recruiting
  • Non Hodgkin Lymphoma
  • R-CHOP + acalabrutinib
  • Southampton, Hampshire, United Kingdom
  • +6 more
2021-08-16
Aug 16, 2021
I
Mixed Molecular Clinical Index (MMCI) in Diffuse Large B-cell Lymphoma (DLBCL)
Recruiting
  • Diffuse Large B Cell Lymphoma
  • molecular characterization
  • Meldola, FC, Italy
  • +3 more
2021-02-25
Feb 25, 2021
K
Safety and Efficacy of KTE-C19 in Combination With Atezolizumab in Adults With Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Active, not recruiting
Has Results
  • Refractory Diffuse Large B Cell Lymphoma
  • KTE-C19
  • +3 more
  • Duarte, California
  • +4 more
2021-11-30
Nov 30, 2021
M
Study of the Impact of CD34+ Cell Dose on Absolute Lymphocyte Count Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Recruiting
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • +2 more
  • leukapheresis
  • +3 more
  • Omaha, Nebraska
  • +13 more
2022-01-21
Jan 21, 2022
M
Study of E7777 Prior to Kymriah for R/R DLBCL
Recruiting
  • DLBCL
  • +3 more
  • Minneapolis, Minnesota
    University of Minnesota, Masonic Cancer Center
2021-07-08
Jul 8, 2021
U
Acalabrutinib in Combination With R-CHOP for Previously Untreated Diffuse Large B-cell Lymphoma (DLBCL)
Recruiting
  • Diffuse Large B Cell Lymphoma
  • Colchester, Essex, United Kingdom
  • +2 more
2021-10-20
Oct 20, 2021
N
Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas
Recruiting
  • Burkitt Lymphoma
  • +4 more
  • Rituximab
  • +6 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
2022-04-07
Apr 7, 2022
R
Zanubrutinib, Lenalidomide and Rituximab (ZR2) in Elderly Treatment-naive Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib, Lenalidomide and Rituximab (ZR2)
  • Shanghai, Shanghai, China
    Shanghai Ruijin Hospital
2020-09-09
Sep 9, 2020
I
A Study of DPX-Survivac Vaccine Therapy in Patients With Recurrent Survivin-expressing DLBCL - 2018
Terminated
  • Diffuse Large B-Cell Lymphoma
  • Ottawa, Ontario, Canada
  • +1 more
2021-06-16
Jun 16, 2021
X
Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Recruiting
  • Diffuse Large B-cell Lymphoma (DLBCL)
  • Beijing, China
  • +22 more
2021-09-01
Sep 1, 2021
N
Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients - 2021
Completed
  • Diffuse Large B-cell Lymphoma
  • Atlanta, Georgia
  • +4 more
2022-02-18
Feb 18, 2022
O
A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL
Recruiting
  • Relapsed or Refractory Diffuse Large B-cell Lymphoma
  • Yamagata, Japan
    Yamagata University Hospital
2021-10-22
Oct 22, 2021
C
Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients
Recruiting
  • Relapsed Large B-cell Lymphoma
  • +5 more
  • CRC01
  • +2 more
  • Seoul, Korea, Republic of
    Samsung Medical Center
2021-04-29
Apr 29, 2021
C
Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma - 2020
Completed
  • Lymphoma
  • +10 more
  • Los Angeles, California
  • +10 more
2021-05-05
May 5, 2021
A
A Trial of Radiotherapy and Durvalumab in DLBCL and FL
Recruiting
  • Diffuse Large B Cell Lymphoma
  • Follicular Lymphoma
  • Brisbane, Queensland, Australia
  • +2 more
2022-02-14
Feb 14, 2022
W
Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
Active, not recruiting
  • Diffuse Large B Cell Lymphoma
  • Saint Louis, Missouri
    Washington University School of Medicine
2021-05-03
May 3, 2021
A
A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Recruiting
  • Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
  • ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle
  • Beijing, Beijing, China
  • +14 more
2021-07-19
Jul 19, 2021
N
Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma
Not yet recruiting
  • Recurrent B-Cell Non-Hodgkin Lymphoma
  • +5 more
  • Decitabine and Cedazuridine
  • Nivolumab
  • New York, New York
    Laura and Isaac Perlmutter Cancer Center at NYU Langone
2022-04-05
Apr 5, 2022
N
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
Active, not recruiting
  • Diffuse Large B-Cell Lymphoma (DLBCL)
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
2022-03-31
Mar 31, 2022